<DOC>
	<DOC>NCT00822237</DOC>
	<brief_summary>This study will test the safety, tolerability, and immunogenicity of VARIVAX manufactured with the 2007 commercial Varicella-Zoster Virus (VZV) bulk process when concomitantly administered with M-M-R II in healthy children.</brief_summary>
	<brief_title>Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)</brief_title>
	<detailed_description>This treatment has been approved for sale to the public.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject is in good health based on medical history Subject has no history of measles, mumps, rubella, chickenpox, or shingles Subject has previously received measles, mumps, rubella, and/or varicella vaccine either alone or in combination Subject has history of immune disorders Subject has been exposed to chickenpox/shingles, measles, mumps, rubella or varicella within 4 weeks of study start Subject has received an inactivated vaccine within 14 days of first dose of study vaccine Subject has received a live vaccine within 30 days of first dose of study vaccine Subject has received a blood transfusion or bloodderived products within 3 months of receiving study vaccine Subject has had a fever within 72 hours of study start</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>